Established in 1995, headquartered in Hong Kong, and listed on the main board of the Hong Kong Stock Exchange since April 20, 2011 (Stock code: 1011.HK), China NT Pharma Group is the largest fully integrated supply chain and promotional and sales services provider of vaccines as well as the second largest sales and marketing services provider for pharmaceutical products in China. In 2009, NT Pharma held a 23.4% market share in vaccine supply chain and an 8.7% market share in third-party provider of promotional services for leading global and domestic vaccine manufacturers. In addition to the vaccine team, NT Pharma also has a dedicated pharmaceuticals team that focuses on services related to prescription drugs and strives to serve as an effective bridge connecting manufacturers and hospitals and patients. The pharmaceuticals team has established long-term relationships with leading multinational and domestic pharmaceutical manufacturers such as Pfizer, GSK, Beijing Xili, Fudan Zhangjiang and others. Products carried by NT Pharma cover a broad spectrum of therapeutic areas including antibiotics, CNS, oncology and modern Chinese medicine, and also include NT Pharma’s own branded products. The Company also owns and operates a new pharmaceuticals factory (built in 2009) that carries out contract manufacturing for partners and manufactures NT Pharma branded pharmaceutical products.As China’s largest vaccines distributor, NT Pharma is the exclusive distributor of GSK vaccine products in China. The Company is also one of the three major distributors of Pfizer prescription products in China. The Company’s manufacturing facility in Suzhou has more than 150 pharmaceutical and healthcare product licenses from the State Food and Drug Administration of China, among which the psychotropic drug ShuSi® is widely recognized and well received by the Chinese medical community. NT Pharma engages in the production of pharmaceuticals through its subsidiary Suzhou No. 1 Pharmaceutical Co., Ltd.,